**Participant Flow Diagram**

Allocated to **Placebo** (n= 3)

 Received allocated intervention (n=2)

 Did not receive allocated intervention (*infusion stopped early due to recorded AEs*) (n=1)

## Follow-Up

Analysed (n=7)  
 Excluded from analysis (give reasons) (n=0)

## Analysis

Analysed (n=3)  
 Excluded from analysis (give reasons) (n=0)

Lost to follow-up (give reasons) (n=0)

Discontinued intervention (give reasons) (n=0)

Lost to follow-up (give reasons) (n=0)

Discontinued intervention (give reasons) (n=0)

## Enrolment

Allocated to **PolyCAb** (n=7)

 Received allocated intervention (n=7)

 Did not receive allocated intervention (give reasons) (n=0)

## Allocation

Randomized (n=10)

Excluded (n=49)

  Not meeting inclusion criteria (n=35 )

  Declined to participate (n=2)

  Other reasons (n=12)

Assessed for eligibility (n=59)

**Baseline Characteristics**

| **Parameter** | **Statistic** | **Placebo (N=3)** | **PolyCAb 170 mg (N=6)** | **PolyCAb 500 mg (N=1)** | **Overall (N=10)** |
| --- | --- | --- | --- | --- | --- |
| **Age (yrs)** | n | 3 | 6 | 1 | 10 |
| Mean | 40.7 | 48.5 | 47.0 | 46.0 |
| SD | 18.58 | 13.90 | NC | 14.06 |
| ≥ 60 yrs  < 60 yrs | n (%) | 1 (33.3) | 1 (16.7) | 0 (0.0) | 2 (20.0) |
| n (%) | 2 (66.7) | 5 (83.3) | 1(100.0) | 8 (80.0) |
| **Height (m)** | n | 3 | 6 | 1 | 10 |
| Mean | 1.747 | 1.713 | 1.780 | 1.730 |
| SD | 0.1150 | 0.0686 | NC | 0.0782 |
| **Weight (kg)** | n | 3 | 6 | 1 | 10 |
| Mean | 75.03 | 77.25 | 86.70 | 77.53 |
| SD | 7.901 | 6.801 | NC | 7.144 |
| **BMI (kg/m2)** | n | 3 | 6 | 1 | 10 |
| Mean | 24.90 | 26.35 | 27.40 | 26.02 |
| SD | 4.603 | 2.199 | NC | 2.846 |
| **Race:**  Caucasian | n (%) | 2 (66.7) | 6 (100.0) | 1 (100.0) | 9 (90.0) |
| Other: Black African | n (%) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 1 (10.0) |
| **Gender:**  Male | n (%) | 2 (66.7) | 5 (83.3) | 1(100.0) | 8 (80.0) |
| Female | n (%) | 1 (33.3) | 1 (16.7) | 0 (0.0) | 2 (20.0) |
| Clinically significant medical history events | n | 3 | 6 | 1 | 10 |
| n (%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Negative virology tests | n | 3 | 6 | 1 | 10 |
|  | n% | 3 (100%) | 6 (100%) | 1 (100%) | 10 (100%) |
| Negative Drugs of Abuse tests | n | 3 | 6 | 1 | 10 |
|  | n (%) | 3 (100%) | 6 (100%) | 1 (100%) | 10 (100%) |
| Compliance with inclusion/exclusion criteria | n | 3 | 6 | 1 | 10 |
| n (%) | 3 (100%) | 6 (100%) | 1 (100%) | 10 (100%) |

**Outcome measures**

**Primary outcome measures**

|  |  |  |
| --- | --- | --- |
| **Outcome measure** | **Time tested** | **Result** |
| Adverse events | Monitored continuously day 1 - 29 | See Adverse Events Section |
| 12-lead ECGs | Pre-dose, day 1 (2,4,8,12 hours), days 2, 8, 15, 22, 29 | No clinically significant results |
| Vital signs (compared with Pre-dose values) | Pre-dose, day 1 (2,4,8,12 hours), days 2, 8, 15, 22, 29 | No clinically significant results |
| Local tolerability | Day 1(15min, 30 min, 1, 2, 8, 12 hours), days 2,3, 6, 8, 15, 22, 29 | No clinically significant results |
| Laboratory safety tests | Day 1, 3, 8, 15, 22, 29 | No clinically significant results |

**Secondary outcome measures**

| **Pharmacokinetics: Summary of derived PK Parameters** | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Treatment** |  | **Summary Statistic** | **Cmax (µg/mL)** | **Tmax (h)** | **t1/2 (h)** | **AUC0-t (h\*µg/mL)** | **AUC0-inf (h\*µg/mL)** | **AUC%extrapolated (%)** |
| **PolyCAb**  **170 mg**  **(N=6)** |  | n | 6 | 6 | 6 | 6 | 6 | 6 |
|  | Mean | 58.1 | 2.46 | 54.6 | 3160 | 3930 | 20.7 |
|  | SD | 8.14 | 2.9 | 13 | 1180 | 1270 | 7.56 |
|  | CV(%) | 14 | 118 | 23.9 | 37.2 | 32.2 | 36.4 |
|  | Minimum | 49.1 | 0.25 | 32.8 | 1600 | 2450 | 12.9 |
|  | Median | 58.7 | 1.5 | 54.6 | 3100 | 3730 | 19.9 |
|  | Maximum | 66.9 | 8 | 72 | 4860 | 5970 | 34.6 |
|  | Geometric Mean | 57.7 | 1.35 | 53.2 | 2970 | 3760 | 19.7 |
| **PolyCAb**  **500 mg**  **(N=1)** |  | n | 1 | 1 | 1 | 1 | 1 | 1 |
|  | Mean | 176 | 0.5 | 70.2 | 11500 | 14400 | 19.6 |
|  | SD | NC | NC | NC | NC | NC | NC |
|  | CV(%) | NC | NC | NC | NC | NC | NC |
|  | Minimum | 176 | 0.5 | 70.2 | 11500 | 14400 | 19.6 |
|  | Median | 176 | 0.5 | 70.2 | 11500 | 14400 | 19.6 |
|  | Maximum | 176 | 0.5 | 70.2 | 11500 | 14400 | 19.6 |
|  | Geometric Mean | 176 | 0.5 | 70.2 | 11500 | 14400 | 19.6 |

| **Immunogenicity: Summary of Anti-Ovine IgG Titres** | | | | |
| --- | --- | --- | --- | --- |
| **Parameter** | **Statistic** | **Placebo (N=3)** | **PolyCAb 170 mg (N=6)** | **PolyCAb 500 mg (N=1)** |
| **Day 1**  **(Pre-Dose)** | Geometric Mean  (95% CI) | 244.2  (82.3, 724.2) | 183.1  (125.0, 268.4) | 320.0  (NC, NC) |
| **Day 8** | Geometric Mean  (95% CI) | 224.0  (97.7, 513.4) | 315.8  (174.2, 572.2) | 449.0  (NC, NC) |
| **Day 15** | Geometric Mean  (95% CI) | 239.0  (88.0, 648.8) | 396.7  (206.0, 764.0) | 706.0  (NC, NC) |
| **Day 22** | Geometric Mean  (95% CI) | 250.8  (114.5, 549.2) | 357.2  (199.1, 641.0) | 571.0  (NC, NC) |
| **Day 29** | Geometric Mean  (95% CI) | 205.2  (94.6, 445.3) | 318.8  (166.4, 610.8) | 519.0  (NC, NC) |

| **Immunogenicity: Summary of Fold-Increase in Anti-Ovine IgG Antibody Titres** | | | | |
| --- | --- | --- | --- | --- |
| **Parameter** | **Statistic** | **Placebo (N=3)** | **PolyCAb 170 mg (N=6)** | **PolyCAb 500 mg (N=1)** |
| **Day 8** | Geometric Mean Ratio | 0.92 | 1.72 | 1.40 |
| **Day 15** | Geometric Mean Ratio | 0.98 | 2.17 | 2.21 |
| **Day 22** | Geometric Mean Ratio | 1.03 | 1.95 | 1.78 |
| **Day 29** | Geometric Mean Ratio | 0.84 | 1.74 | 1.62 |

**Adverse Events:**

Treatment Emergent Adverse Events

|  | **Placebo (N=3)** | **PolyCAb**  **170 mg**  **(N=6)** | **PolyCAb**  **500 mg**  **(N=1)** | **Overall (N=10)** |
| --- | --- | --- | --- | --- |
| **Number of TEAEs** | 7 | 20 | 1 | 28 |
| **Number (%) of Subjects Reporting ≥ 1:** |  |  |  |  |
| TEAE | 2 (66.7) | 6 (100.0) | 1 (100.0) | 9 (90.0) |
| Serious TEAE | 0 (0.0) | 1 (16.7)1 | 0 (0.0) | 1 (10.0)1 |
| TEAE Leading to Withdrawal | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| **Number (%) of Subjects with TEAE by Maximum Severity:** |  |  |  |  |
| Mild | 1 (33.3) | 1 (16.7) | 0 (0.0) | 2 (20.0) |
| Moderate | 1 (33.3) | 0 (0.0) | 0 (0.0) | 1 (10.0) |
| Severe | 0 (0.0) | 5 (83.3)2 | 1 (100.0)3 | 6 (60.0)2,3 |
| **Number (%) of Subjects with TEAE by Greatest Relationship to IMP:** |  |  |  |  |
| Almost Definite | 1 (33.3) | 5 (83.3) | 1 (100.0) | 7 (70.0) |
| Probable | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Possible | 1 (33.3) | 1 (16.7) | 0 (0.0) | 2 (20.0) |
| Unlikely | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Unrelated | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| N/A | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |

**Skin and Subcutaneous Tissue Disorders**

| **SOC:**  Preferred Term | **Number of Subjects (%)** | | | |
| --- | --- | --- | --- | --- |
| **Placebo (N=3)** | **PolyCAb**  **170 mg**  **(N=6)** | **PolyCAb**  **500 mg**  **(N=1)** | **Overall (N=10)** |
| **SKIN & SUBCUTANEOUS TISSUE DISORDERS:** |  |  |  |  |
| Urticaria | 0 (0.0) | 5 (83.3)2 | 0 (0.0) | 5 (50.0) |
| Angioedema | 0 (0.0) | 2 (33.3)1 | 0 (0.0) | 2 (20.0)1 |
| Cold Sweat | 1 (33.3) | 0 (0.0) | 0 (0.0) | 1 (10.0) |
| Pruritus | 1 (33.3) | 0 (0.0) | 0 (0.0) | 1 (10.0) |
| Rash Erythematous | 0 (0.0) | 1 (16.7) | 0 (0.0) | 1 (10.0) |
| Rash Generalised | 0 (0.0) | 0 (0.0) | 1 (100.0)3 | 1 (10.0) |